Discover and read the best of Twitter Threads about #mucosalimmunity
Most recents (2)
I'm excited to share with you our recent @biorxivpreprint where we demonstrate that @vaxart mucosal Ad5 #SARSCoV2 vaccines not only protected against disease but also reduced transmission after post-#vaccination #SARSCoV2 infection in a hamster model. biorxiv.org/content/10.110… A🧵/
If you follow me, you are well aware of my obsession w/ #mucosalimmunity.😂Protection generated at mucosal surfaces is at the crux of one of the biggest questions we need to answer during this unique phase of the #pandemic - How do we decrease #SARSCoV2 #transmission to others.
Considering most of the world is unimmunized (including most kids <12), the possibility that a vaccinated individual with a post-vaccination infection (aka #breakthrough) can spread #SARSCoV2 is a public health risk. We need #transmissionblocking strategies.
Excited to share our work by @BenIsraelow et al published today. We asked what are the roles of antibodies vs. T cells in controlling primary infection, reinfection, and vaccine-mediated protection? (1/n)
science.org/doi/10.1126/sc…
science.org/doi/10.1126/sc…
First, we asked if B cells are needed to control primary infection. We used muMT mice (devoid of B cells) transduced with AAV-hACE2. These mice had only a slight delay in viral clearance. Thus B cells are not necessary for controlling primary SARS-CoV-2 infection. (2/n) 
However, in mice that have neither T cells nor B cells (RAG-/-), SARS-CoV-2 persisted with no sign of clearance. Thus, innate immunity is insufficient, and adaptive immunity is required to control primary infection. (3/n)
